Goldman Sachs Group Inc. lifted its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 72.4% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 206,234 shares of the medical research company’s stock after buying an additional 86,595 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.44% of Enzo Biochem worth $2,277,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Hillsdale Investment Management Inc. purchased a new position in shares of Enzo Biochem during the 2nd quarter valued at $167,000. Voya Investment Management LLC lifted its stake in shares of Enzo Biochem by 12.0% during the 2nd quarter. Voya Investment Management LLC now owns 25,059 shares of the medical research company’s stock valued at $277,000 after buying an additional 2,682 shares in the last quarter. Mckinley Capital Management LLC Delaware lifted its stake in shares of Enzo Biochem by 39.8% during the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 455,042 shares of the medical research company’s stock valued at $5,024,000 after buying an additional 129,538 shares in the last quarter. OxFORD Asset Management LLP lifted its stake in shares of Enzo Biochem by 0.9% during the 2nd quarter. OxFORD Asset Management LLP now owns 277,752 shares of the medical research company’s stock valued at $3,066,000 after buying an additional 2,563 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Enzo Biochem by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,026,647 shares of the medical research company’s stock valued at $22,376,000 after buying an additional 193,246 shares in the last quarter. Institutional investors own 62.07% of the company’s stock.

In other Enzo Biochem news, CFO Barry W. Weiner sold 54,126 shares of the stock in a transaction on Wednesday, October 25th. The shares were sold at an average price of $10.11, for a total transaction of $547,213.86. Following the transaction, the chief financial officer now directly owns 1,423,367 shares of the company’s stock, valued at $14,390,240.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP James Michael O’brien sold 22,866 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $10.28, for a total transaction of $235,062.48. Following the transaction, the executive vice president now directly owns 34,886 shares in the company, valued at $358,628.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 149,393 shares of company stock worth $1,512,802. Insiders own 9.50% of the company’s stock.

WARNING: This story was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://theolympiareport.com/2017/10/31/goldman-sachs-group-inc-has-2-28-million-position-in-enzo-biochem-inc-enz.html.

A number of research analysts recently weighed in on the stock. TheStreet cut shares of Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th. BidaskClub cut shares of Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th.

Enzo Biochem, Inc. (NYSE ENZ) opened at 9.86 on Tuesday. The stock’s market cap is $458.95 million. Enzo Biochem, Inc. has a 1-year low of $5.79 and a 1-year high of $12.04. The company’s 50 day moving average is $10.46 and its 200-day moving average is $10.36.

Enzo Biochem Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.